Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

512
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
512
Dementia01:30

Dementia

458
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
458
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

699
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
699

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in body composition in genetic C9orf72 carriers: The role of the hypothalamus and thalamus.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Astrocytic lipid dysregulation as an early driver of neurodegeneration.

Nature reviews. Neurology·2026
Same author

CRYAB is compromised in pathologically affected oligodendrocytes in multiple system atrophy.

Brain pathology (Zurich, Switzerland)·2026
Same author

Ultra-rare variants in LAMA2 are risk factors for frontotemporal dementia and motor neuron disease.

Human molecular genetics·2026
Same author

Location and mapping of the human rostromedial tegmental nucleus and associated midbrain inhibitory nuclei regulating dopamine neurons.

Brain structure & function·2026
Same author

The exposome of brain aging across 34 countries.

Nature medicine·2026

Related Experiment Video

Updated: Dec 27, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.0K

Uncovering pathophysiological changes in frontotemporal dementia using serum lipids.

Katherine Phan1, Ying He1, Russell Pickford2

  • 1The University of Sydney, Brain and Mind Centre & Central Clinical School, Sydney, NSW, Australia.

Scientific Reports
|February 29, 2020
PubMed
Summary

Lipidomics analysis reveals specific alterations in serum lipids, such as cardiolipin and acylcarnitine, in patients with frontotemporal dementia (FTD). These findings highlight lipid changes as potential biomarkers for detecting FTD

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.9K
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

8.2K

Related Experiment Videos

Last Updated: Dec 27, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.0K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.9K
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

8.2K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Metabolomics

Background:

  • Lipids are crucial brain components, and their dysregulation is implicated in neurodegenerative diseases.
  • Frontotemporal dementia (FTD) involves brain atrophy, lipid loss, and dyslipidemia, but the underlying lipid-disease link is unclear.

Purpose of the Study:

  • To investigate the role of serum lipid alterations in frontotemporal dementia (FTD) pathophysiology.
  • To explore the connection between dyslipidemia and FTD using advanced lipidomics techniques.

Main Methods:

  • Utilized mass spectrometry-based lipidomics to analyze serum samples from FTD patients and controls.
  • Investigated key FTD pathophysiological aspects: mitochondrial dysfunction, inflammation, and oxidative stress.
  • Correlated specific lipid changes with conventional disease markers.

Main Results:

  • Identified significant alterations in cardiolipin, acylcarnitine, lysophosphatidylcholine, platelet-activating factor, O-acyl-ω-hydroxy fatty acid, and acrolein in FTD patients.
  • Observed strong correlations among these altered lipids, indicating shared pathophysiological pathways.
  • Validated lipidomic findings with measurements of ATP, cytokines, and calcium levels.

Conclusions:

  • Serum lipidomics can detect pathophysiological changes associated with frontotemporal dementia (FTD).
  • Specific lipid alterations serve as potential biomarkers for FTD diagnosis and understanding disease mechanisms.